IRLAB Therapeutics AB
STO:IRLAB A
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.9
19.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
IRLAB Therapeutics AB
IRLAB Therapeutics AB
Total Current Liabilities
IRLAB Therapeutics AB
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Total Current Liabilities
kr36.7m
|
CAGR 3-Years
21%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Total Current Liabilities
kr429.8m
|
CAGR 3-Years
52%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Total Current Liabilities
kr403.3m
|
CAGR 3-Years
27%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Total Current Liabilities
kr357.1m
|
CAGR 3-Years
61%
|
CAGR 5-Years
77%
|
CAGR 10-Years
N/A
|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Total Current Liabilities
kr20.5m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Total Current Liabilities
kr23.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
IRLAB Therapeutics AB
Glance View
IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
See Also
What is IRLAB Therapeutics AB's Total Current Liabilities?
Total Current Liabilities
36.7m
SEK
Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's Total Current Liabilities amounts to 36.7m SEK.
What is IRLAB Therapeutics AB's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
24%
Over the last year, the Total Current Liabilities growth was 14%. The average annual Total Current Liabilities growth rates for IRLAB Therapeutics AB have been 21% over the past three years , 24% over the past five years .
You don't have any saved screeners yet
